Subscribe

Grifols, S.A. (GRF.MC)

EUR9.02 +0.18 (+2.06%)
ES BME Healthcare Drug Manufacturers - General
Address Avinguda de la Generalitat, 152 8174
Barcelona, ES
CEO Jose Ignacio Abia Buenache
Website grifols.com
IPO 2006-05-17
ISIN ES0171996087

Explore sections of this company profile

Also trades on Madrid Stock Exchange · GRF.MC (EUR) NASDAQ Global Select · GRFS (USD) Other OTC · GIFLF (USD) Other OTC · GIFOF (USD) Other OTC · GIKLY (USD)
Description

Grifols, S.A., a Spanish company established in 1940 and headquartered in Barcelona, specializes in the comprehensive process of acquiring, manufacturing, preparing, and distributing therapeutic products, with a primary focus on those derived from plasma. The company operates through several key divisions: Bioscience, Hospital, Diagnostic, and Bio Supplies, among others. The Bioscience division is dedicated to the research, development, production, and commercialization of plasma-derived medicines and other cutting-edge solutions. These are designed to treat individuals suffering from chronic, rare, widespread, and life-threatening medical conditions, with its product portfolio including immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division supplies a range of non-biological pharmaceutical products, clinical nutrition items, intravenous (IV) therapy solutions, and various medical devices and supplies. Grifols' Diagnostic division develops and markets advanced diagnostic tools that support healthcare professionals across the entire patient care continuum, from prevention and screening to accurate diagnosis, prognosis, and ongoing disease and treatment monitoring. Finally, the Bio Supplies division provides essential biological materials for life-science research, clinical trials, and the manufacturing of both pharmaceutical and diagnostic goods. Collectively, Grifols' offerings enable healthcare providers to effectively diagnose and treat a broad spectrum of medical conditions, such as hemophilia, various immune deficiencies, and infectious diseases. Its diverse client base includes public and private sector organizations, wholesalers, distributors, group purchasing organizations (GPOs), blood banks, hospitals, care institutions, and national health systems. Grifols also maintains a technology collaboration agreement with Mondragon.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
EUR9.02 +0.18 (+2.06%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
1.18
Float Shares
417.32M
Free Float %
61.3%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-1.47% -4.92% -2.58% -19.74% -19.74% -18.69% +3.69% -21.69% -63.07% -52.09% +241.18%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Analyst Consensus (7 ratings, all time) Buy
Price Targets & DCF
Current price
9.02
DCF (Unlevered) 43.34 +380.5%
DCF (Levered) 71.98 +698.0%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 67% Bullish
Rating 2026-05 Change
Strong Buy 2 0
Buy 6 0
Hold 3 0
Sell 1 0
Strong Sell 0 0
Quality scores
Altman Z-Score
1.05
Distress
Piotroski F-Score
6 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
3 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Drug Manufacturers - General: +6.6%
    +4.3% Q1'26: -4.8% (vs Q1'25)
  • ✓
    EPS growth Drug Manufacturers - General: +18.2%
    +152.2% ★ Q1'26: +25.3% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - General: +36.0%
    +6.4% Q1'26: +3.4% (vs Q1'25)
  • ✗
    EBIT margin Drug Manufacturers - General: +19.4%
    +16.6% Q1'26: +14.6% (vs Q1'25)
  • ✗
    ROIC Drug Manufacturers - General: +10.2%
    +6.6% Q1'26: +4.7% (vs Q1'25)
  • ✗
    Share dilution Drug Manufacturers - General: +0.0%
    +1.1% Q1'26: +0.0% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×
    6.99× Q1'26: 6.85× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (1.17) × ERP
WACC = 41% × Ke + 59% × Kd (7.2%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 43.34 Current price: 9.02
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
5 Rev. Ana.
7 EPS Ana. 		Dec 2027
11 Rev. Ana.
10 EPS Ana. 		Dec 2028
8 Rev. Ana.
7 EPS Ana. 		Dec 2029
7 Rev. Ana.
2 EPS Ana. 		Dec 2030
7 Rev. Ana.
5 EPS Ana.
Revenue
3.93B
est: 3.88B (+1.5%)
4.05B
est: 4.06B (-0.2%)
4.32B
est: 4.36B (-1.0%)
4.49B
est: 4.45B (+0.7%)
5.10B
est: 5.07B (+0.6%)
5.34B
est: 5.36B (-0.3%)
4.93B
est: 5.14B (-4.1%)
6.06B
est: 5.93B (+2.3%)
6.59B
est: 6.81B (-3.2%)
7.21B
est: 7.15B (+0.9%)
7.52B
est: 7.52B (+0.1%)
7.72B
7.61B – 7.83B
+2.7% YoY
8.19B
7.82B – 8.50B
+6.1% YoY
8.67B
8.65B – 8.70B
+5.9% YoY
9.31B
9.02B – 9.55B
+7.4% YoY
9.65B
9.35B – 9.90B
+3.6% YoY
EBITDA
1.12B
est: 822.24M (+36.5%)
1.15B
est: 860.56M (+33.4%)
1.19B
est: 924.63M (+28.8%)
1.26B
est: 944.57M (+33.3%)
1.44B
est: 1.07B (+34.4%)
1.42B
est: 1.14B (+25.3%)
944.03M
est: 1.09B (-13.5%)
1.21B
est: 1.26B (-3.5%)
1.18B
est: 1.31B (-9.6%)
1.61B
est: 1.37B (+17.2%)
1.25B
est: 1.44B (-13.4%)
1.48B
1.46B – 1.50B
+2.7% YoY
1.57B
1.50B – 1.63B
+6.1% YoY
1.67B
1.66B – 1.67B
+5.9% YoY
1.79B
1.73B – 1.83B
+7.4% YoY
1.85B
1.80B – 1.90B
+3.6% YoY
EBIT
914.86M
est: 583.27M (+56.9%)
941.56M
est: 610.45M (+54.2%)
945.26M
est: 655.90M (+44.1%)
1.00B
est: 670.05M (+49.2%)
1.14B
est: 762.04M (+49.8%)
1.10B
est: 805.73M (+36.7%)
584.27M
est: 773.91M (-24.5%)
805.80M
est: 891.80M (-9.6%)
740.08M
est: 1.60B (-53.7%)
1.32B
est: 1.68B (-21.2%)
1.25B
est: 1.76B (-29.1%)
1.81B
1.78B – 1.84B
+2.7% YoY
1.92B
1.83B – 1.99B
+6.1% YoY
2.03B
2.03B – 2.04B
+5.9% YoY
2.18B
2.12B – 2.24B
+7.4% YoY
2.26B
2.19B – 2.32B
+3.6% YoY
Net Income
532.15M
est: 601.73M (-11.6%)
545.46M
est: 586.29M (-7.0%)
662.70M
est: 664.27M (-0.2%)
596.64M
est: 679.54M (-12.2%)
625.15M
est: 691.58M (-9.6%)
618.55M
est: 686.23M (-9.9%)
265.33M
est: 477.58M (-44.4%)
208.28M
est: 326.39M (-36.2%)
59.32M
est: 156.74M (-62.2%)
156.92M
est: 399.44M (-60.7%)
401.89M
est: 497.29M (-19.2%)
516.62M
488.03M – 688.59M
+3.9% YoY
709.95M
658.08M – 882.87M
+37.4% YoY
865.88M
798.44M – 1.63B
+22.0% YoY
1.09B
1.04B – 1.12B
+25.5% YoY
1.21B
1.16B – 1.25B
+11.6% YoY
SGA
736.44M
est: 735.07M (+0.2%)
775.27M
est: 769.33M (+0.8%)
860.35M
est: 826.60M (+4.1%)
814.78M
est: 844.43M (-3.5%)
942.82M
est: 960.37M (-1.8%)
985.62M
est: 1.02B (-2.9%)
1.06B
est: 975.33M (+8.8%)
1.19B
est: 1.12B (+5.9%)
1.25B
est: 1.25B (+0.0%)
1.17B
est: 1.32B (-11.4%)
1.18B
est: 1.38B (-14.5%)
1.42B
1.40B – 1.44B
+2.7% YoY
1.51B
1.44B – 1.56B
+6.1% YoY
1.60B
1.59B – 1.60B
+5.9% YoY
1.71B
1.66B – 1.76B
+7.4% YoY
1.78B
1.72B – 1.82B
+3.6% YoY
EPS
0.78
est: 0.89 (-11.9%)
0.80
est: 0.86 (-7.2%)
0.97
est: 0.98 (-0.7%)
0.87
est: 1.00 (-13.0%)
0.91
est: 1.02 (-10.5%)
0.90
est: 1.01 (-10.8%)
0.39
est: 0.70 (-44.5%)
0.31
est: 0.48 (-35.4%)
0.09
est: 0.23 (-61.8%)
0.23
est: 0.58 (-60.5%)
0.58
est: 0.73 (-20.1%)
0.85
0.71 – 1.00
+17.2% YoY
1.10
0.96 – 1.28
+29.3% YoY
1.42
1.16 – 2.37
+29.5% YoY
1.58
1.52 – 1.63
+10.9% YoY
1.76
1.69 – 1.82
+11.6% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-08 B 3/5 1/5 3/5 4/5 1/5 3/5 4/5
2026-05-07 B 3/5 1/5 3/5 4/5 1/5 3/5 4/5
2026-05-06 B 3/5 1/5 3/5 4/5 1/5 3/5 4/5
2026-05-05 B 3/5 1/5 3/5 4/5 1/5 3/5 4/5
2026-05-04 B 3/5 1/5 3/5 4/5 1/5 3/5 4/5
2026-04-30 B 3/5 1/5 3/5 4/5 1/5 3/5 4/5
2026-04-29 B 3/5 1/5 3/5 4/5 1/5 3/5 4/5
2026-04-28 B 3/5 1/5 3/5 4/5 1/5 3/5 4/5
2026-04-27 B 3/5 1/5 3/5 4/5 1/5 3/5 4/5
2026-04-24 B 3/5 1/5 3/5 4/5 1/5 3/5 4/5
2026-04-23 B 3/5 1/5 3/5 4/5 1/5 3/5 4/5
2026-04-22 B 3/5 1/5 3/5 4/5 1/5 3/5 4/5
2026-04-21 B 3/5 1/5 3/5 4/5 1/5 3/5 4/5
2026-04-20 B 3/5 1/5 3/5 4/5 1/5 3/5 4/5
2026-04-17 B 3/5 1/5 3/5 4/5 1/5 3/5 4/5
2026-04-16 B 3/5 1/5 3/5 4/5 1/5 3/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
834.30M
OE per share TTM
1.22
Owner's Yield
13.71%
Maintenance CapEx ratio
139.95%
Maint CapEx / Avg PPE
58.5%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 138 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 iShares EURO STOXX Small UCITS ETF DJSC.L 0.94% 4.58M 0.40%
2 Sparkline International Intangible Value ETF DTAN 0.47% 69.0K 0.55%
3 Touchstone Dynamic International ETF TDI 0.46% 341.7K 1.19%
4 UBS MSCI EMU Small Cap UCITS ETF EUR dis UEFD.DE 0.44% 3.23M 0.33%
5 iShares MSCI EMU Small Cap UCITS ETF CES1.L 0.43% 4.50M 0.58%
6 WisdomTree International AI Enhanced Value Fund AIVI 0.42% 252.6K 0.58%
7 iShares STOXX Europe Small 200 UCITS ETF (DE) EXSE.DE 0.40% 2.76M 0.20%
8 Amundi IBEX 35 UCITS ETF Acc CS1.L 0.39% 3.95M 0.30%
9 Amundi IBEX 35 UCITS ETF Dist LYXIB.MC 0.39% 3.95M 0.30%
10 Amundi MSCI EMU Small Cap ESG Broad Transition UCITS ETF Dist MMS.PA 0.37% 2.64M 0.40%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
52.5K
Shares Outstanding
680.57M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Jose Ignacio Abia Buenache Chief Executive Officer & Director 4M male
Daniel Segarra Head of Investor Relations & Sustainability and Vice President — —
David Ian Bell Chief Corporate Affairs & Legal Officer — male
Enrique de la Torre Chief Compliance Officer — male
Jaime Gonzalez Peralta Chief Digital Information Officer — male
Jorg Schuttrumpf Chief Scientific Innovation Officer — —
Lluis Pons Gomez Senior Vice President of Strategy & Chief Operating Officer Office — male
Miguel Louzan Chief Digital Information Officer — male
Montse Ribas Chief Communications and Reputation Officer — female
Rahul Srinivasan Chief Financial Officer — male
Roland Wandeler President of Biopharma Business Unit — —
Sergio Roura Adell President of Commercial Tech Support — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - General